Literature DB >> 18082737

Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial.

Peter G McGovern1, Sandra A Carson, Huiman X Barnhart, Evan R Myers, Richard S Legro, Michael P Diamond, Bruce R Carr, William D Schlaff, Christos Coutifaris, Nicholas A Cataldo, Michael P Steinkampf, John E Nestler, Gabey Gosman, Phyllis C Leppert, Linda C Giudice.   

Abstract

We investigated whether poor adherence with metformin tablets may have contributed to the poor success rates seen in the metformin-containing arms of the Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial. Median adherence for both metformin and clomiphene citrate tablets was within acceptable limits and unrelated to ovulation: thus, failure to comply with physician recommendations for metformin dosing was not the reason for low ovulation and pregnancy rates in the PPCOS Trial.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082737      PMCID: PMC2570771          DOI: 10.1016/j.fertnstert.2007.09.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  The natural history of medication compliance in a drug trial: limitations of pill counts.

Authors:  P Rudd; R L Byyny; V Zachary; M E LoVerde; C Titus; W D Mitchell; G Marshall
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

2.  Treatment of infertility in the polycystic ovary syndrome.

Authors:  Tarekegn Geberhiwot; Alan F Jones
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

3.  Time to stop counting the tablets?

Authors:  T Pullar; S Kumar; H Tindall; M Feely
Journal:  Clin Pharmacol Ther       Date:  1989-08       Impact factor: 6.875

4.  Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications.

Authors:  R A Deyo; T S Inui; B Sullivan
Journal:  J Rheumatol       Date:  1981 Nov-Dec       Impact factor: 4.666

5.  Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.

Authors:  Richard S Legro; Huiman X Barnhart; William D Schlaff; Bruce R Carr; Michael P Diamond; Sandra A Carson; Michael P Steinkampf; Christos Coutifaris; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Linda C Giudice; Phyllis C Leppert; Evan R Myers
Journal:  N Engl J Med       Date:  2007-02-08       Impact factor: 91.245

6.  Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily.

Authors:  T Pullar; A J Birtwell; P G Wiles; A Hay; M P Feely
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

7.  Dosage frequency and drug-compliance behaviour--a comparative study on compliance with a medication to be taken twice or four times daily.

Authors:  W Kruse; W Eggert-Kruse; J Rampmaier; B Runnebaum; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  7 in total
  3 in total

1.  Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study.

Authors:  Marte Myhre Reigstad; Ritsa Storeng; Tor Åge Myklebust; Nan Birgitte Oldereid; Anne Katerine Omland; Trude Eid Robsahm; Louise Annette Brinton; Siri Vangen; Kari Furu; Inger Kristin Larsen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-01-20       Impact factor: 4.254

2.  Incorporating patient preference into the management of infertility in women with polycystic ovary syndrome.

Authors:  Ugochi C Okoroafor; Emily S Jungheim
Journal:  Patient Prefer Adherence       Date:  2012-05-24       Impact factor: 2.711

3.  Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth.

Authors:  Lawrence Engmann; Fangbai Sun; Richard S Legro; Michael P Diamond; Heping Zhang; Nanette Santoro
Journal:  Hum Reprod       Date:  2020-12-01       Impact factor: 6.918

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.